Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Spero Therapeutics Inc (SPRO)

Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis GlobeNewswire - Fri Dec 19, 2025

CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare...

SPRO : 2.25 (-1.75%)
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Nov 28, 2025

CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for...

SPRO : 2.25 (-1.75%)
Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update GlobeNewswire - Thu Nov 13, 2025

Results from PIVOT-PO Phase 3 trial evaluating tebipenem HBr in complicated urinary tract infection (cUTI) presented as IDWeek late-breaker in October 2025 Spero’s development partner, GSK, plans...

SPRO : 2.25 (-1.75%)
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025 GlobeNewswire - Tue Nov 4, 2025

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for...

SPRO : 2.25 (-1.75%)
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs) GlobeNewswire - Tue Oct 21, 2025

Data presented at IDWeek 2025 after study stopped early for efficacy Primary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment 1 Data will be...

SPRO : 2.25 (-1.75%)
GSK : 55.08 (-3.08%)
Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek GlobeNewswire - Tue Oct 14, 2025

CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare...

SPRO : 2.25 (-1.75%)
Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update GlobeNewswire - Tue Aug 12, 2025

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC) Spero,...

SPRO : 2.25 (-1.75%)
Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025 GlobeNewswire - Tue Aug 5, 2025

CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare...

SPRO : 2.25 (-1.75%)
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee GlobeNewswire - Wed May 28, 2025

SPRO : 2.25 (-1.75%)
GSK.LN : 2,084.880 (-1.42%)
GSK : 55.08 (-3.08%)
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update GlobeNewswire - Tue May 13, 2025

SPRO : 2.25 (-1.75%)

Barchart Exclusives

South Korea’s Stock Market Just Fell 12% in 1 Day. Here's What It Means for Investors. Barchart - 49 minutes ago
The iShares MSCI South Korea ETF (EWY) just experienced a sudden dramatic drop. Here's what to know about what happened and what it means for U.S. investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot